Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lowry Stanford

Pediatrics Hattiesburg, MS Medical Doctor

NPI 1013972306 CMS profile 847622

39 Franklin Rd, Ste 220, Hattiesburg, MS 39402

Open in the dashboard

General payments

$1,537

94 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lowry Stanford of Hattiesburg, MS is reported in the CMS Open Payments database as having received $1,537 across 94 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $76 4
2024 General $218 12
2023 General $172 10
2022 General $220 13
2021 General $249 15
2020 General $258 16
2019 General $344 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lowry Stanford
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Lowry Stanford were reported at $76. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Lowry Stanford Pediatrics median Middle half National median
2019 $344 $86 $31–$183 $163
2020 $258 $49 $22–$110 $114
2021 $249 $68 $27–$158 $132
2022 $220 $77 $30–$173 $149
2023 $172 $88 $33–$190 $160
2024 $218 $94 $34–$206 $164
2025 $76 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tris Pharma Inc $325 21 payments
  2. Corium, Inc. $205 15 payments
  3. GlaxoSmithKline, LLC. $188 12 payments
  4. Pfizer Inc. $181 10 payments
  5. Merck Sharp & Dohme Corporation $175 10 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $119 7 payments
  7. Sanofi Pasteur Inc. $108 5 payments
  8. Ironshore Pharmaceuticals Inc. $102 5 payments
  9. Supernus Pharmaceuticals, Inc. $60 3 payments
  10. Shire North American Group Inc $51 4 payments
  11. Other $24 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,537 94 payments
Products named General payments · program years 2019–2025
  1. Azstarys $205 15 payments
  2. BEXSERO $188 12 payments
  3. GARDASIL 9 $175 10 payments
  4. VYVANSE $170 11 payments
  5. PEDIARIX $168 11 payments
  6. MENVEO $168 11 payments
  7. Dyanavel XR $140 9 payments
  8. Quillivant XR $139 10 payments
  9. VAXNEUVANCE $116 6 payments
  10. TRUMENBA $107 7 payments
  11. Other $1,101 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

94 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record